Enanta Pharmaceuticals, Inc.

ENTA

US29251M1062

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 21:00:00 12/12/2025 GMT			5-day change	1st Jan Change
14.73 ^USD	+4.17%		+0.89%	+156.17%

11-30	Certain restricted stock units of Enanta Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 30-NOV-2025.	CI
11-30	Certain Options of Enanta Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 30-NOV-2025.	CI

Enanta Pharmaceuticals Q4 revenue rises, helped by higher sales of AbbVie's MAVYRET/MAVIRET

Published on 11/17/2025 at 09:14 pm GMT

Reuters

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Enanta Pharmaceuticals, Inc.

11-30	Certain restricted stock units of Enanta Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 30-NOV-2025.	CI
11-30	Certain Options of Enanta Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 30-NOV-2025.	CI
11-30	Certain Common Stock of Enanta Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 30-NOV-2025.	CI
11-17	Enanta Pharmaceuticals Fiscal Q4 Loss Narrows, Revenue Rises	MT
11-17	Enanta Pharmaceuticals Q4 revenue rises, helped by higher sales of AbbVie's MAVYRET/MAVIRET	RE
11-17	Enanta Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended September 30, 2025	CI
10-20	Enanta Pharmaceuticals, Inc. Presents New Data for Zelicapavir, its N-Protein Inhibitor and EDP-323, L-Protein Inhibitor	CI
10-02	Enanta Pharmaceuticals announces closing of upsized public offering of common stock	RE
10-02	Enanta Pharmaceuticals Closes Stock Offering	MT
10-01	Jefferies Upgrades Enanta Pharmaceuticals to Buy From Hold, $20 Price Target	MT
10-01	Traders Weigh US Government Shutdown, Fueling Premarket Losses for US Equity Futures	MT
10-01	Top Premarket Decliners	MT
10-01	Enanta Pharmaceuticals Prices $65 Million Common Stock Offering; Shares Fall Pre-Bell	MT
10-01	Enanta Pharmaceuticals prices upsized offering of 6,500,000 shares at $10 each	RE
09-30	Enanta Pharmaceuticals Launches Public Offering of Common Shares	MT
09-30	Enanta Pharmaceuticals announces $50 million public offering of common stock	RE
09-29	Enanta Pharmaceuticals, Inc. - Special Call
09-29	Enanta Pharmaceuticals Says Zelicapavir Misses Phase 2 Primary Endpoint, But Shows RSV Improvement	MT
09-29	Enanta's RSV treatment helps speed up recovery in study, shares surge	RE
09-29	Enanta Pharmaceuticals reports positive Phase 2b results for RSV drug zelicapavir	RE
09-29	Enanta Pharmaceuticals Reports Positive Topline Results from Its Phase 2B Study of Zelicapavir for the Treatment of Respiratory Syncytial Virus in High-Risk Adults	CI
09-03	Enanta Pharmaceuticals, Inc. Announces Demise of Paul J. Mellett Jr, Chief Financial and Administrative Officer	CI
09-03	Enanta Pharmaceuticals, Inc. Announces Demise of Paul J. Mellett Jr, Chief Administrative Officer	CI
09-03	Enanta Pharmaceuticals Chief Financial, Administrative Officer Dies	MT
08-27	Enanta Pharmaceuticals appoints Harry R. Trout as interim principal financial officer	RE

Chart Enanta Pharmaceuticals, Inc.

Duration

Period

ENTA: Dynamic Chart

Enanta Pharmaceuticals, Inc. is a clinical-stage biotechnology company. The Company is engaged in the discovery and development of small molecule drugs with an emphasis on indications in virology and immunology. The Companyâs clinical programs are focused on respiratory syncytial virus (RSV) and its earlier-stage immunology pipeline aims to develop treatments for inflammatory diseases by targeting key drivers of the type 2 immune response, including receptor tyrosine kinase (KIT) and STAT6 inhibition. The Company has two clinical-stage product candidates for RSV, which are zelicapavir and EDP-323. Glecaprevir, a protease inhibitor discovered by the Company, is part of one of the treatment regimens for curing chronic hepatitis c virus (HCV) infection and is sold by AbbVie in various countries under the tradenames MAVYRET (U.S.) and MAVIRET (ex-U.S.) (glecaprevir/pibrentasvir). The Company also has development programs in virology for SARS-CoV-2 and Hepatitis B virus.

Employees

120

Sector

Pharmaceuticals

Calendar

02-08 - Q1 2026 Earnings Release

More about the company